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Innovations
Metaphore Pharmaceuticals:
Mimicking Nature’s Enzyme
enzyme can no longer remove su- 400 molecular weight on average.
“And, they have the same or greaterperoxide sufficiently. When that
activity as the native human en-happens, you have superoxide-
When the Monsanto Corporation,
through its G.D. Searle division,
made a strategic decision in the late
1990s to focus on its COX-2 pain zyme,” says Dunton.mediated cell and tissue damage.
and antiinflammatory drug program, Two forms of SOD are found inOur technology is aimed at removing
the effect was not only the creation the body: a copper/zinc form and athis radical oxygen species and
of its blockbuster drug, Celebrex, manganese form located in the mito-downregulating inflammation.”
but also the launch of a spin-off chondria. All of Metaphore’s com-The initial research team at Mon-
company focusing on other pain and pounds are based on the manga-santo postulated that if it could cre-
inflammation treatment strategies. nese form of the SOD enzyme. “Theate a mimetic of the SOD enzyme to
That company, Metaphore Pharma- manganese form is the least toxic ofaugment the body’s own SOD levels,
ceuticals, now based in St. Louis, the metals used by the enzyme andthey could help any disease where
MO, grew from the research team at it is the most crucial one,” explainsinflammation played a key role.
Searle who were targeting the natu- Salvemini.“That’s the platform for the com-
ral enzyme superoxide dismutase SOD-based drug therapy is notpany,” says Dunton. “The thinking
(SOD), an essential component in new. In the 1980s, a bovine-derived,behind the company’s name is that
limiting damage caused by superox- copper/zinc injectable form of the
ide, a naturally toxic free radical SOD enzyme, Orgotein, was tested
harmful to cells and tissues. in humans with some exciting data,
“In inflammation, the [en-“The focus of the company is particularly in arthritis and in radia-
tion-induced damage, providingbased on what the chemists did at dogenous SOD] enzyme
Searle initially, then was fine-tuned proof of concept that removing su-can no longer removeand developed here at Metaphore,” peroxide has a beneficial outcome.
superoxide sufficiently.says Alan Dunton, MD, Metaphore However, problems arose due to the
large size of the molecule and immu-CEO. “They created drug-like small When that happens, you
molecules mimicking the activity of nogenic responses due to its bovinehave superoxide-medi-superoxide dismutase in the hu- source. Orgotein is now classified
ated cell and tissue dam-man body.” by the FDA as an orphan drug for
the treatment of familial amyotro-Superoxide: Toxic Free Radical age. Our technology is
Free radical oxygen, such as super- phic lateral sclerosis and is used inaimed at removing thisoxide, is formed every time the body veterinary formulations for treat-
radical oxygen speciesuses oxygen in respiration. “And, su- ment of soft tissue inflammation.
“But our SOD mimetics are smallerperoxide anions are also some of the and downregulating in-
primary mediators of inflammation, and very selective for superoxide,”flammation.” – Danielacausing toxic damage if not re- explains Salvemini. “You do not
want to remove all of the reactivemoved by the body’s own supply Salvemini, PhD, Senior
of superoxide dismutase,” explains oxygen species in the body.”V.P. of Research, Meta-
Dunton, who joined the privately Supplementing Pain and
phoreheld, 32-member company early Inflammation Relief
this year. “We have identified superoxide as
Following a proinflammatory stim- a novel mediator of pain and SOD
these small drug molecules are mi-ulus, the body responds by upregu- mimetics as novel nonnarcotic anal-
metics that stand for somethinglating cytokine production, increas- gesics for the management of pain
greater, which is the SOD enzymeing neutrophil infiltration and of multiple origin,” says Salvemini.
itself,” explains Dunton. “So, ouradhesion, and superoxide anion “Therefore, the foundation of our
drugs are metaphors, if you will, ofproduction. “We have also known pain relief technology is to use SOD
the greater enzyme.”for a number of years that during mimetics to selectively remove su-
The SOD Scavengerinflammatory disease progression peroxide and therefore address the
In all animals, including humans, su-there is a downregulation of the en- pain associated with conditions like
peroxide dismutase circulates in thedogenous SOD enzyme,” explains acute inflammation, neuropathic
body to remove superoxide onceDaniela Salvemini, PhD, Senior Vice pain, cancer pain, and pain associ-
formed. The human SOD enzyme isPresident of Research at Metaphore ated with chronic use of morphine,
a metalloprotein of about 32K mo-and a member of the original Mon- an event also known as opiate toler-
lecular weight, but the moleculessanto SOD research team. “In in- ance,” says Salvemini. The idea is
to supplement the body’s own sup-flammation, the [endogenous SOD] Metaphore creates are about 300–
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ply of SOD that cannot keep up with glutamate-mediated activation of ucts and they are both injectable
therapies,” says Dunton. “We areall the free radical oxygen formed in the NMDA receptor. Removal of su-
peroxide by SOD mimetic inhibits ni-an inflammatory state. “These also developing novel oral agents more
active than those products andinclude chronic diseases like rheu- tration of this pathway, inhibiting
central sensitization and pain.matoid arthritis, inflammatory bowel cheaper to produce.” Metaphore will
be initiating human testing with andisease, and even some cardiovas- “In summary, our studies so far
have unraveled a critical role for su-cular ischemic conditions,” adds oral agent in 2004.
Other CompetitorsDunton. peroxide in the nociceptive signaling
cascade both peripherally and cen-At the recent Society for Neurosci- “Other companies are developing
metal-based drugs with the intent ofence 2003 conference, Dr. Salvemini trally,” says Salvemini. “The discov-
ery of superoxide in pain opens apresented a novel role for superox- removing SOD,” acknowledges Sal-
vemini. And others have pursuedide in acute inflammatory pain. “One new therapeutic strategy for the de-
velopment of novel, nonnarcotic anti-pathway involves modification of the much larger SOD molecules in the
past, “but we are the first companyinflammatory response in develop- hyperalgesic agents that then reduce
pain, acute and chronic, without effi-ment of hyperalgesia, or increased to successfully synthesize small
molecule SOD mimetics,” claims Dun-sensitivity to pain at the site of the cacy limits or significant side effects.”
The company hinges its long-termpainful stimuli,” she says, “and the ton. “And smaller, easier to produce
mimetics are fundamental to ourother is a novel central pathway goals on the comparatively smaller
molecular weights of its compounds,identified at the level of the spinal success where others have failed
with larger SOD derivatives or evencord.” hopefully allowing them to develop
orally active agents as well as paren-Metaphore researchers have native enzyme therapies.” Meta-
phore will be forming alliances in theshown that one of their lead mimet- teral therapies. “Though our lead
agents are parenteral therapies, weics, M40403, reduces inflammation future with larger pharma compa-
nies that have the wherewithal to doand hyperalgesia in in vivo models are now really focusing on the devel-
opment of oral compounds,” saysboth peripherally and centrally. At the large-scale 5,000–6,000 person
clinical trials and subsequent large-the site of inflammation, antihyperal- Salvemini.
Injectable Lead Agentsgesic actions were associated with scale marketing required for a pri-
mary care indication like rheumatoidinhibition of cytokines and peroxyni- Metaphore currently has two identi-
fied lead agents in human clinicaltrite formation and attenuation of arthritis or inflammatory bowel dis-
ease. This explains why the com-poly-ADP-ribose-polymerase acti- testing. “Our human proof of con-
cept in pain was achieved this yearvation. Additionally, M40403 inhib- pany has recently opened a Fort
Lee, NJ office where they will centerited a central hyperalgesic response with our M40403 mimetic,” says
Dunton. Phase II tests were recentlyby preventing nitration and subse- their clinical and business develop-
ment capabilities. “It makes sensequent deactivation of endogenous completed with this IV therapy. The
first indication Metaphore is aimingspinal SOM. “This key finding sup- to reason we will be interested in
partnering with companies thatports the concept that nitration and for is treatment of pain in combina-
tion with opiates or morphine-likesubsequent inactivation of endoge- know the pain/inflammation markets
intimately,” says Dunton.nous spinal SOM is a critical event in drugs. Over time, cancer patients of-
ten require higher doses of mor-the hyperalgesic response, possibly
Chemistry & Biology invites yourby allowing the levels of superoxide phine-like, narcotic agents for pain
comments on this topic. Pleaseto remain elevated,” according to relief. “We have seen that our agents
write to the editors at chembiol@Salvemini. can prevent the tolerance from oc-
cell.com.“In addition, our results have dem- curring or can actually reverse it
once developed,” explains Dunton.onstrated that during pain, nitration Alice A. McCarthy is a freelance science
of key proteins involved in the regu- “This would be a tremendous ad- writer based in Gloucester, MA (alice@
alicemccarthy.com).lation of glutamate occurs by super- vance because of the side effects
caused by morphine including seda-oxide,” explains Salvemini. Gluta-
mate is a key excitatory amino acid tion, constipation, respiratory de-
pression, and altered sensoria.”implicated in central sensitization
associated with pain of multiple ori- M40419, also an IV agent, is in
phase I safety trials. “And animalgin. “Our results show that gluta-
mine synthase (the glial enzyme in- studies have shown we now also
have found orally active molecules,”volved in metabolizing glutamate
into nontoxic glutamine), the gluta- explains Dunton. “That is critical
since it will allow us to expand intomate transporter (responsible for
taking up glutamate from the synap- treatment of chronic disease indica-
tions where you could not go withtic cleft), and the N-methyl-D-aspar-
tate (NMDA) receptor subunits are an injectable agent.” He explains
that the best way to estimate thekey targets for superoxide-mediated
nitration and subsequent inactiva- commercial opportunity for nonnar-
cotic pain medications is to look attion,” says Salvemini. Overall, inacti-
vation provides a sustained source molecules like Remicade or Enbrel.
“Those are huge blockbuster prod-of glutamate in the synaptic cleft and
